throbber
Proc. Natl. Acad. Sci. USA
`Vol. 81, pp. 6851-6855, November 1984
`Immunology
`
`Chimeric human antibody molecules: Mouse antigen-binding
`domains with human constant region domains
`(transfect.lon/protoplast fusion/calcium phosphate transrection/intronk controlling tkments/transfectoma)
`
`
`SHERIE L. MORRISON*, M. JACQUELINE JOHNSONt, LEONARD A. HERZENBERGt, AND VERNON T. Q1:t:
`Coluf!lbi� University.
`_ollege of Physicians and Surgeons.
`
`for Cancer Research. •Depanment of Microbiology and the Cancer Center. Institute
`
`
`New York, NY 10032: tDepanment of Genetics, Stanford University School of Medicine.
`
`Stanford, CA 94305; and *Becton-Dickinson
`Monoclonal Center. 2375 Garcia Avenue , Mountain View, CA 94043
`
`_C
`
`Contributed by Leonard A. Heri.enberg, August I, 1984
`
`ABSTRACT We have created mouse-human antibody
`molecules of defined antigen-binding specificity by taking the
`variable region genes of a mouse antibody-producing myeloma
`ceU line with known antigen-binding specificity and joining
`them to human immunoglobulin constant region genes using
`recombinant DNA techniques. Chimeric genes were construct­
`ed that utilized the rearranged and expressed antigen-binding
`variable region cxons from the myeloma cell line S107, which
`produces an lgA (K) anti-phosphocholine antibody. The
`heavy chain variable region exon was joined to human lgG 1 or
`IgG2 heavy chain constant region genes, and the light chain
`variable region exon from the same myeloma was joined to the
`human " light chain gene. These genes we.re translected into
`mouse myeloma ceU lines, generating translormed ceUs that
`produce chimeric mouse-human lgG (K) or lgG (K) anti-pbos·
`phocholine antibodies. The transformed ceU lines remained tu­
`morigenic in mice and the chimeric molecules were present in
`the ascltic nuids and sera of tumor-bearing mice.
`
`The capability to transfer immunoglobulin genes into lym­
`phoid cells where they produce protein in quantities suffi­
`cient for structural studies (1-3) provides us with the oppor­
`tunity to generate and characterize novel immunoglobulin
`molecules. Cloned variable (V) region genes from mouse or
`rat hybridoma cell lines can be ligated to human constant (C)
`region genes and we would expect that these chimeric genes
`can be transfected into mouse myeloma cells, which then
`will produce novel human antibody molecules. We would
`thus produce antibodies that are largely human but which
`have antigen-binding specificities generated in mice. The ad­
`ditional potential for in vitro manipulation and alteration of
`both the antigen-binding site and the structures correlated
`with biological effector functions of these antibody mole­
`cules using recombinant DNA techniques would introduce a
`powerful approach for further understanding antibody struc­
`ture, function, and immunogenetics.
`As we show here, both chimeric mouse heavy chain V re­
`gion exon (VH}-human heavy chain C region genes and chi­
`meric mouse light chain V region exon (V,.}-human K light
`chain gene constructs are expressed when transfected into
`mouse myeloma cell lines. When both chimeric heavy and
`light chain genes are transfected into the same myeloma cell,
`an intact tetrameric (H2L2) chimeric antibody is produced.
`In this study we used VH and V,. exons from the mouse phos­
`phocholine (PCho)-binding antibody-producing S107 myelo­
`ma cell line (4, 5). Chimeric mouse-human anti-PCho anti­
`bodies were produced in culture by appropriate transfected
`cell lines or by "transfectomas" obtained when such cell
`lines are injected into mice.
`
`MATERIALS AND METHODS
`Chimeric Genes. The cloned S107 VH and S107 v .. genes
`were gifts from Matthew Scharff (Albert Einstein College of
`Medicine, Bronx, NY). The S107 VH gene was spliced to
`human lgGl and lgG2 C region genes by using Sal I linkers
`as shown in Fig. lA. Both constructs were inserted into the
`vector pSV2�H-gpt (1, 6). The S107 V,. gene was spliced to
`the human K gene at a unique HindUI site located in the large
`intron between the K light chain joining and C (J,. and C,.)
`region exons as shown in Fig. lB. This chimeric light chain
`gene construct was inserted into both PSV2�H-gpt and
`pSV2-neo plasmid vectors (7).
`Transfection. Protoplast fusion and calcium phosphate
`precipitation techniques (1, 8, 9) were used to transfect these
`chimeric immunoglobulin genes into the J558L myeloma cell
`line (a >. light chain-producing mouse myeloma cell line) and
`an immunoglobulin nonproducing derivative of the P3 my­
`eloma cell line. Mycophenolic acid (GIBCO) was used for
`selection of cells transfected with pSV2�-gpt vectors as de­
`scribed (1, 3). G418 (GIBCO) at 1.0 mg/ml was used for se­
`lection of cells transfected ,with pSV2-neo vectors (7).
`Light and heavy chain chimeric immunoglobulin genes
`were transfected sequentially by protoplast fusion using
`G418 selection for the chimeric light chain gene vector and
`mycophenolic acid for the chimeric heavy chain gene vector.
`The protoplast fusion transfection procedure used was as de­
`scribed (1).
`Transfection using the calcium phosphate precipitation
`procedure was done by transfecting a mixture of 40 µg each
`of the chimeric light and chimeric heavy chain pSV2�H-gpt
`vectors into 5 x 106 cells. Mycophenolic acid was used to
`select for transformed cell lines as described (1).
`Antigen Binding. PCho binding of antibody secreted into
`the culture supernates of transfected cell lines was analyzed
`by using a solid-phase radioimmunoassay described previ­
`ously (10). PCho-keyhole limpet hemocyanin antigen was
`bound to 96-well polyvinyl plates; bindint of chimeric anti­
`PCho antibodies was detected by using 1 I-labeled protein
`A or 1251-labeled-anti-human lgG. PCho-binding antibodies
`in biosynthetically labeled culture supernates and cell ly­
`sates of transfected cell lines also were analyzed by binding
`the biosynthetically labeled antibody to PCho-coupled Seph­
`arose 48 (Pharmacia) and then eluting the bound antibody
`with PCho-hapten. The bound and eluted antibody was ex­
`amined by NaDodS04/polyacrylamide gel electrophoresis
`(NaDodS04/PAGE). Biosynthetic-labeling procedures were
`as described (11).
`ldlotope Analysis. Three hybridoma anti-idiotope antibod­
`ies, also kindly provided by Matthew Scharff and Angela
`
`The publication costs of this anicle were defrayed in part by page charge
`
`
`payment. This article must therefore be hereby marked "advertisement"
`in accordance with 18 U.S.C. §1734 solely to indicate this fact.
`
`Abbreviations: V, variable; C, constant; J,joining; "'heavy chain;
`L• light chain; PCho, phosphoeholine; kb, kilobase(s); NEPHGE.
`nonequilibrium pH gradient electrophoresis.
`
`6851
`
`1 of 5
`
`BI Exhibit 1031
`
`

`

`6852
`
`Immunology: Morrison et al.
`
`Proc. Natl. Acad. Sci. USA 81 (1984)
`
`A
`
`bJD.HI
`
`(Seel) Sel I (Hind Ill)
`
`pSV26H-S 107 HuG 1
`
`t
`
`t
`
`Mouse VDJ
`
`Human constant region
`
`pBR322 orl
`
`SV40 ori
`
`B
`
`bDJ.HI t Mouse VJ
`
`pSV26H-S107 Huk
`
`Human kappa
`
`bm.HI
`
`t
`
`pBR322 orl
`
`SV40 ori
`
`Eco-gpt or
`Eco-neo
`
`F1G. 1. Schematic diagrams (not drawn to scale) of the chimeric mouse-human heavy chain gene vector (A) and the chimeric light chain
`gene vectors (B). DNA fragment sizes are as follows: HindlII-BamHI human IgGl (HuGl) or lgG2 (HuG2) heavy chain gene, 7 kilobases (kb);
`mouse Sl07 VH gene, 4.5 kb; HindIIl-BamHl human c. gene (HuK), 10 kb; and mouse Sl07 v. gene, 3.5 kb. The Hindlll sites in the human
`IgGl and IgG2 heavy chain genes were ligated to the Sac I site of the mouse Sl07 VH gene with Sal I linkers.
`
`Guisti (Albert Einstein College of Medicine), were usea to
`analyze the Vw-VL (Lis light chain) domain structure of the
`chimeric human anti-PCho antibodies. These antibodies
`(TC102.l.2, Tl39.2, and Tl56.l.l), recognizing three inde­
`pendent idiotopes (12), were used to immunoprecipitate bio­
`synthetically labeled material eluted with PCho from the
`PCho-Sepharose 4B matrix. Immunoprecipitates were ana­
`lyzed by NaDodS04/PAGE.
`Chain Composition. Monoclonal anti-hu­
`Immunoglobulin
`man lgG and anti-human K antibodies (Becton-Dickinson)
`were used to immunoprecipitate biosynthetically labeled chi­
`meric human anti-PCho antibodies for analyses using two­
`dimensional nonequilibrium pH gradient PAGE (NEPH'.GE)
`(11, 13). PCho-coupled Sepharose 4B also was used for af­
`finity purification.
`Tunicamycin
`lmmunoglobulln Heavy Chain Glyoosylation.
`
`(Calbiochem-Behring) was used to inhibit asparagine-linked
`glycosylation of biosynthetically labeled antibody from
`mouse cell lines producing mouse-human chimeric immuno­
`globulins (11). PCho-binding antibody from tunicamycin­
`treated cells was analyzed by NaDodS04/PAGE. Proce-
`
`dures for tunicamycin treatment were as described (11).
`Chimeric Mouse-Human Antibody Production in Mice.
`Transfected J558L cells producing chimeric mouse-human
`antibody were injected intraperitoneally into BALB/c mice
`(106 cells per mouse). Sera and ascitic fluids from tumor­
`bearing mice were analyzed for human anti-PCho antibody
`by a solid-phase radioimmunoassay (10) and by immunoelec­
`trophoresis using a polyclonal anti-human lgG antiserum.
`
`RESULTS
`We obtained expression of chimeric mouse V region-human
`C region genes in transfected J558L and the immunoglobulin
`nonproducing P3 myeloma cell lines. When both light chain
`and heavy chain chimeric genes (see Fig. 1) were expressed
`in the same cell, tetrameric (H2L2) antigen-binding antibod­
`ies were obtained. Biosynthetically labeled antibody mole­
`cules secreted by J�58L cells expressing chimeric genes
`were bound and hapten-eluted from PCho-Sepharose 4B.
`Autoradiograms of two-dimensional NEPHGE analyses
`(Fig. 2) show immunoglobulin polypeptide chains of the ex-
`
`2 of 5
`
`BI Exhibit 1031
`
`

`

`Immunology: Morrison et al
`
`Proc. Natl Acad. Sci. USA 81 (1984) 6853
`
`pected charge and relative molecular mass. Identical two­
`dimensional gel analysis results were obtained with immuno­
`precipitates by using monoclonal anti-human K and IgG anti­
`bodies. Similar results were obtained when the chimeric
`IgG2 (K) antibodies produced in the transfected nonproduc­
`ing P3 cell line were analyzed. Since the recipient P3 cell line
`does not produce endogenous immunoglobulin polypeptide
`chains, only the chimeric mouse-human heavy and light
`chains were seen (data not shown). PCho binding by the chi­
`meric antibody produced in the J558L cell line required the
`specific association of both the V H and V L domains of the
`Sl07 myeloma protein connected to human C region poly­
`peptides. Antibody secreted by transfected J558L cells ex­
`pressing only the chimeric heavy chain and the endogenous
`J558L light chain did not bind PCho (data not shown).
`Further verification of the appropriate polypeptide folding
`of the mouse V H and V L domains attached to human C re­
`gion polypeptide chains was done by analyses detecting the
`presence of idiotopes known to occur on the parental Sl07
`PCho-binding antibody molecule. Three monoclQnal anti­
`idiotope antibodies-two recognizing idiotopes requiring the
`association of light and heavy V region domains (TC102.l.2
`and Tl39.2) and the third (Tl56.l.l) recognizing an epitope
`preseqt on the heavy chain V region domain (12)-were
`found to react with the mouse-human chimeric anti-PCho
`antibodies (see Fig. 3). This is good evidence that the mouse
`Sl07 antigen-binding domains have folded into their intend­
`ed structures.
`The conformation of IgG heavy chain C regions depends
`
`Basic
`
`A
`
`HuG2-
`
`B
`
`HuGl-
`
`•
`
`t
`
`•
`
`t
`
`HuK
`
`Acidic
`
`-67
`
`-45
`
`-30
`
`-67
`
`-45
`
`-30
`
`•
`
`t
`
`..
`
`t
`
`J558>..
`
`a
`
`b
`
`c
`
`d
`
`H2L2- -----
`
`Fm. 3. Autoradiograph of nonreduced NaI>odSO./PAGE anal­
`yses of />Cho-binding material from a chimeric IgG2 (K) antibody­
`producing J558L cell line immunoprecipitated with Staphylococcus
`aureus protein A (lane a), monoclonal anti-human K antibody (lane
`b). and anti-idiotope antibodies TC102.l.2 and Tl56.l.l (lanes c and
`d).
`
`on the presence of the asparagine-linked carbohydrate
`moeity in the CH2 domain of the molecule (4). The loss of
`this carbohydrate chain affects profoundly the overall do­
`main structure of this part of the immunoglobulin molecule.
`Concomitant with this structural change, the catabolism rate
`of the molecule is increased and biological effector functions
`such as complement-fixation are lost (14). Glycosylation of
`the mouse-human chimeric antibodies in mouse myeloma
`cells was deduced by determining the molecular masses of
`antibodies synthesized in the presence and absence of tuni­
`camycin, an antibiotic inhibitor of asparagine-linked glyco­
`sylation. Fig. 4 is an autoradiogram of NaDodS04/PAGE
`analysis of glycosylated and nonglycosylated chimeric heavy
`and light chains produced in transfected mouse myeloma
`cells. Though we cannot be certain that in the absence of
`tunicamycin the appropriate asparagine residue in the CH2
`domain is glycosylated, clearly, the lower molecular mass of
`the heavy chain synthesized in the presence of tunicamycin
`is as expected if a single N-linked carbohydrate were absent
`
`a
`
`b
`
`-·-
`
`-67
`
`-45
`
`-30
`
`-20
`
`FIG. 2. Autoradiographs of two-dimensional NEPHGE gels of
`mouse-human chimeric IgG2 (K) anti-PC antibody (A) and mouse­
`human chimeric IgGl (K) anti-PC antibody (B). Antibodies synthe­
`sized by transfected J558L cells were affi nity purified with PCho­
`Sepharose 4B. The electrophoretic mobility of the J558L >.chain had
`been determined previously (1). Size markers are shown in k.Da.
`
`FIG. 4. Autoradiograph of reduced NaI>odSO./PAGE analyses
`of chimeric IgG2 (K) antibody synthesized in the presence (lane a)
`and absence (lane b) of tunicamycin. Size markers are shown in
`k.Da.
`
`3 of 5
`
`BI Exhibit 1031
`
`

`

`6854 Immunology:
`Morrison et al
`
`Proc. Natl Acad. Sci. USA 81 (1984)
`
`anti-human lgG
`
`the immunogenicity of antibodies used in vivo, relative to
`
`
`
`monoclonal mouse hybridoma antibodies currently being
`used (15). Further, since the same V region can be joined to
`
`
`
`any C region, it is possible to use the C region of an appropri­
`
`ate human heavy chain isotype that will exhibit desired bio­
`F10. S. lmmunoclcctrophoresis of ascitic fluid from a BALB/c
`
`
`
`logical effector functions.
`
`mouse bearing a J558L transfectoma producing chimeric IgG2 (ic)
`The use of mammalian lymphoid cells to produce these
`with a polyclonal anti-human lgG
`anti-PCho antibodies developed
`
`
`
`antibodies rather than a prokaryotic expression system as­
`antiserum.
`
`
`sures that any post-translational modifications of the anti­
`from the polypeptide chain. Note that the light chain band is
`
`
`
`
`body molecules as they are synthesized, processed, folded,
`
`
`
`not affected by tunicamycin treatment. From these data, we
`
`and assembled in the eukaryotic endoplasmic reticulum are
`
`
`
`conclude that the mouse myeloma cell appropriately glyco­
`
`
`carried out correctly. For example, the immunoglobulins en­
`sylates the human heavy chain.
`
`coded by the transfected mouse-human chimeric immuno­
`
`When transfected J558L cells producing the human IgG2
`
`
`globulin genes in both mouse recipient cells were glycosylat­
`
`(K) chimeric anti-PCho antibody were grown as an ascitic
`
`
`ed, bound antigen, and presumably would be treated as nor­
`
`
`tumor in BALB/c mice, analyses of sera and ascitic fluids
`
`
`mal immunoglobulins if injected into humans. This obviates
`
`showed the presence of significant quantities of anti-PCho­
`
`
`the need for any post-synthetic in vitro modification or as­
`
`
`binding antibodies by radioimmunoassay. Fig. 5 shows the
`
`
`
`sembly that is required with prokaryotic synthesis of immu­
`
`
`results of immunoelectrophoretic analysis of ascitic fluids
`
`
`
`
`noglobulin polypeptides to produce functional antibody mol­
`
`
`from these transfectoma-bearing mice. Polyclonal anti-hu­
`
`ecules (16). Furthermore, we have shown that transfectomas
`
`man antiserum (a gift of E. A. Kabat, Columbia University,
`
`produce useable amounts of human antibodies either in tis­
`
`New York) was used to demonstrate the presence of human
`sue culture or in mice.
`immunoglobulin.
`
`Based on our previous experience with
`
`It is now feasible to shuffle exons or carry out other kinds
`mouse hybridoma-antibody production in mice, we conclude
`
`
`
`of directed mutagenesis to explore the human antibody mol­
`
`
`that the amounts of immunoglobulin visualized by this im­
`
`
`
`ecules C region structures required for carrying out diverse
`
`munoelectrophoretic analysis are similar to the levels seen
`
`
`
`functions. It is conceivable that an altered antibody
`antibody
`
`with lower-producing mouse bybridomas in vivo.
`
`
`
`molecule more effective in specific functions than naturally
`
`
`Transfectomas producing chimeric heavy and light chains
`occurring antibody molecule can be created. In a similar
`
`were produced either by cotransfection of both genes using
`
`manner, it should be possible to modify V regions to alter
`
`
`
`calcium phosphate precipitation or by sequential protoplast
`
`
`
`their interactions with antigen. Even more exciting would be
`
`fusion using vectors with different drug markers. For proto­
`de novo.
`
`to construct antigen-binding sites
`
`plast fusion, the heavy chains were introduced first on a
`A limitation yet to be overcome is the low frequency of
`
`
`
`plasmid expressing the Eco-gpt gene. One heavy chain-pro­
`
`transformants that produce chimeric light chains. The chi­
`(see Fig. lB) has the mouse
`meric light chain gene construct
`
`fusion ducing cell line then was transfected by protoplast
`
`
`
`with a plasmid containing the light chain gene and the neo
`
`V,. gene coupled to the presumed human intronic controlling
`
`
`
`marker. Transformants resistant to both mycophenolic acid
`
`
`element (ICE) or "enhancer"-that is, this construct con­
`and G418 were assayed for their production of anti-PCho
`
`tains the human intron with a sequence homologous to the
`
`
`
`antibodies. Of 77 transformants analyzed, only 7 were posi­
`
`
`established mouse ICE sequence (17). In contrast, the heavy
`
`tive for antibody by radioimmunoassay and only 2 of these
`
`
`
`chain chimeric mouse-human polypeptide is expressed effi­
`
`
`ciently. In the latter construct (sec Fig. lA), the ICE se­
`
`
`
`were found to be producing significant quantities of K light
`
`
`
`chain. In cotransfection experiments usins the calcium phos­
`
`
`quence is mouse-derived. Thus, the lower expression fre­
`
`
`
`phate precipitation protocol, the same phenomenon was ob­
`
`
`quency of the chimeric light chain gene may reflect a species
`
`served. Analyses of a large number of independent transfor­
`
`
`
`preference for the effective interaction of the ICE sequence
`
`( <10%) of the transfected cell mants revealed that a minority
`
`
`
`with factors or elements controlling immunoglobulin expres­
`
`lines produced both chimeric heavy and light chain polypep­
`
`sion in mouse lymphoid cells. This suggestion is consistent
`
`tides. Since our own unpublished data using the calcium
`
`with our earlier finding that the mouse light chain gene, pre­
`
`
`sumably due to its ICE sequence, is not expressed efficiently
`
`
`
`phosphate precipitation procedure demonstrate that two in­
`
`in a rat myeloma cell line (1). Construction of chimeric genes
`
`
`tact mouse immunoglobulin genes cotransfected into the
`
`
`of using entire mouse intronic sequences and elimination
`same cell, using the same protocol as described here, coex­
`
`
`
`most human intronic sequences, to determine if these will be
`
`press both gene products in the majority of transformed cell
`
`
`expressed efficiently, await further investigation.
`
`lines, these results suggest that appropriate transcriptional
`
`In this work we have taken the initial steps toward con­
`
`
`or translational controlling clements are absent in the chi­
`
`
`
`structing and efficiently expressing unique imrnunoglobulin
`
`meric light chain gene construction or that required tran­
`
`
`molecules. We expect that this technique will permit an in­
`
`scriptional or translational factors are absent in the mouse
`
`
`creased understanding of the structural and dynamic require­
`
`
`cell Lines transfected here.
`
`
`
`ments of antibody functions. It also will facilitate develop­
`DISCUSSION
`
`
`ment of antibody molecules for immunodiagnosis and immu­
`The opportunity to use recombinant DNA techniques to con­
`
`
`
`notherapy.
`struct novel antibody genes and then to produce antibody
`
`
`
`molecules in mammalian lymphoid cells transfected with
`We thank Letitia Wims and Linda Nakamura Roark, who provid­
`
`these genes in appropriate vectors provides a new approach
`ed invaluable
`
`
`assistance with these experiments. We also thank
`
`
`to understanding the structure, function, and immune prop­
`Olivia Gagliani
`
`
`for her patience in preparing this manuscript. This
`
`erties of antibody molecules. The use of chimeric mouse­
`research was supported in part by Grants K04 AI00408, Al 19042,
`
`AI 08917, CA 16858, CA 22736, CA 13969, and CA G4681 from the
`
`human antibody gene constructs permits us to study "near­
`of Health, Grant IMS-360 from the American
`National Institutes
`
`
`human" antibodies with desired antigen-binding specific­
`
`
`Cancer Society. and Grant SPO 13712-02-00 from the Becton-Dick­
`
`
`ities. For clinical applications, human antibody molecules
`
`inson Monoclonal Center.
`
`
`constructed by using recombinant DNA techniques should
`
`
`complement human-human hybridoma antibodies as useful
`
`
`
`immunotherapeutic and diagnostic reagents. The use of hu­
`1. Oi, V. T .. Morrison, S. L., Herzenbcrg,
`L.A. & Berg, P.
`
`might decrease or eliminate man or near-human antibodies
`
`
`(1983) Proc. Natl. Acad. Sci. USA 80, 825-829.
`
`4 of 5
`
`BI Exhibit 1031
`
`

`

`Immunology: Morrison et al.
`
`Proc. Natl. Acad. Sci. USA 81 (1984) 6855
`
`2. Gillies, S. D., Morrison, S. L., Oi, V. T. & Tonegawa, S.
`(1983) Cell 33, 717-728.
`3. Ochi, A .. Hawley, R. G., Hawley, T., Shulman, M. J., Trau­
`necker, A .. Kohler, G. & Hozumi, N. (1983) Proc. Natl. Acad.
`Sci. USA 80, 6351-6355.
`4. Kwan, S. P., Rudikoff, S., Seidman, J. G., Leder, P. &
`Scharff, M. D. (1981) J. Exp. Med. 153, 1366-1370.
`5. Clarke, C., Berenson, J., Governman, J., Boyer, P. D.,
`Crews, S., Siu, G. & Calame, K. (1982) Nucleic Acids Res. 10,
`7731-7749.
`6. Mulligan, R. C. & Berg, P. (1980) Science 209, 1422-1427.
`7. Mulligan, R. C. & Berg, P. (1981) Proc. Natl. Acad. Sci. USA
`78, 2072-2076.
`8. Sandri-Goldin, R. M., Goldin, A. L., Levine, M. & Glorioso,
`J. C. (1981) Mo/. Cell. Biol. l, 743-752.
`9. Chu, G. & Sharp, P. A. (1981) Gene 13, 197-202.
`
`10. Oi, V. T. & Herzenberg, L.A. (1979) Mo/. Immuno/. 16,
`1005-1017.
`11. Oi, V. T., Bryan, V. M .. Herzenberg, L.A. & Herzenberg,
`L. A. (1980) J. Exp. Med. 151, 1260-1274.
`12. Desaymaid. C., Guist, A. M. & Sharff, M. D. (1984) Mo/. lm­
`munol., in press.
`13. O'Farrell, P. Z .. Goodman, H. M. & O'Farrell, P. H. (1977)
`Cell 12, 1133-1142.
`14. Nose, M. & Wigzell, H. (1983) Proc. Natl. Acad. Sci. USA 80,
`6632-6636.
`15. Miller, R. A. & Levy, R. (1981) Lancet i, 226-229.
`16. Boss, M.A., Kenton, J. H., Wood, C. R. & Emtage, J. S.
`(1984) Nucleic Acids Res. 12, 3791-3806.
`17. Morrison, S. L. & Oi, V. T. (1984) Annu. Rev. lmmunol. 2,
`239-256.
`
`5 of 5
`
`BI Exhibit 1031
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket